Clinical Trials

POE16-01, A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Hematologic Malignancies

Cancer Type

Multiple Sites

ClinicalTrials.gov Identifier

NCT02932280

Principal Investigator

Anne–Marie Langevin MD

For more information about this study
View Details

About This Study

The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.